Related Experiment Video

Updated: Apr 13, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.2K

Fluorescent virus lights up on a new drug for chronic hepatitis E

Jérôme Gouttenoire1,2, Philip Meuleman3

  • 1Service of Gastroenterology and Hepatology, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland Jerome.Gouttenoire@chuv.ch.

Gut
|April 11, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
ANTIVIRAL THERAPYCHRONIC HEPATITISMODELS, ANIMALS

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Related Experiment Videos

Last Updated: Apr 13, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Related Concept Videos

Hepatitis01:25

Hepatitis

59
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
59

Articles linked to this work by shared authors, journal, and citation graph.

Transferrin receptor 1 is required for efficient hepatitis E virus production.

PLoS pathogens·2026

[Hepatitis A-E: the essentials].

Revue medicale suisse·2025

Higher Hepatitis E Seroprevalence in Workers in the Pig Sector in Flanders, Belgium: Results From a Seroprevalence Case-Control Study.

Zoonoses and public health·2025

HEV ORF2 protein-antibody complex deposits are associated with glomerulonephritis in hepatitis E with reduced immune status.

Nature communications·2024

High-throughput single-cell screening of viable hybridomas and patient-derived antibody-secreting cells using punchable microwells.

Artificial cells, nanomedicine, and biotechnology·2024

A genome-wide CRISPR/Cas9 screen identifies a role for Rab5A and early endosomes in hepatitis E virus replication.

Proceedings of the National Academy of Sciences of the United States of America·2023

Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis.

Gut·2026

Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study.

Gut·2026

Multinational prevalence and burden of paediatric disorders of gut-brain interaction: results of the Rome Foundation paediatric global study.

Gut·2026

Ciliogenic pancreatopathy reveals a link between ciliopathies and exocrine pancreatic disease.

Gut·2026

Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.

Gut·2026

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Gut·2026

A Multimodal Graph Neural Network Based on MRI Radi-omics for Prognostic Prediction in Locally Advanced Cervical Squamous Cell Carcinoma.

Cancer control : journal of the Moffitt Cancer Center·2026

Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.

JNCI cancer spectrum·2026

Outcomes That Matter in Gastrointestinal Cancer Care: A Focus Group Study of Patient-Centred Outcomes Identified by Patients and Care Partners.

Health expectations : an international journal of public participation in health care and health policy·2026

Nicotinamide Metabolism Constrains Memory CD8+ T Cell Formation Through a Putative HS1BP3-SIRT1-FOXO3-BCL6 Axis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.

Inflammatory bowel diseases·2026

Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor.

Inflammatory bowel diseases·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us